BioMedNewsBreaks Archive - Page 191 of 194

ThursdayFeb 06, 2020 11:08 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced its February 4, 2020 receipt of notice from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") for continued listing on The Nasdaq Capital Market. Accordingly, the company has regained compliance with the Bid Price Rule and Nasdaq considers the matter closed. To view the full press release, visit http://nnw.fm/Fi5Dq About Genprex, Inc. Genprex, Inc. is…

WednesdayFeb 05, 2020 1:37 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today provided a clinical update and focus for its Oncoprex(TM) immunogene therapy program for 2020. According to the update, Genprex will prioritize the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (“NSCLC”). Genprex, on January 14, 2020, received U.S Food and Drug Administration (“FDA”) Fast Track Designation for its Oncoprex immunogene therapy in combination with the EGFR tyrosine kinase inhibitor osimertinib (AstraZeneca’s Tagrisso(R), currently its highest grossing product) for the…

WednesdayFeb 05, 2020 11:19 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab

Predictive Oncology (NASDAQ: POAI), together with its subsidiary, TumorGenesis, Inc., today announced that it has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor of its innovative culture media for growing ovarian tumor cells. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological signatures of heterogeneous ovarian cell types while growing them in the laboratory, unlike traditional cell culture media that select for one or two fast growing cell types. “Using these proprietary media our partners have identified 25 cell types from ovarian tumors, which to a large degree…

MondayFeb 03, 2020 10:56 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that it will present at the Noble Capital Markets 16th Annual Investor Conference. Genprex’s presentation is scheduled to take place at 1:30 p.m. EST on Monday, February 17, 2020, at the conference to be held at the Seminole Hard Rock Hotel & Casino in Hollywood, Florida from February 16-18, 2020. According to the update, Genprex CEO Rodney Varner will deliver an overview of the Company and provide updates on its product pipeline, including the Food…

WednesdayJan 29, 2020 10:15 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, non-viral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that, in a recent study, independent researchers reported that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, is a potential target and biomarker for thyroid carcinoma. Genprex has no affiliation with these researchers. The study, published in the International Journal of Molecular Sciences, reports that TUSC2 overexpression decreased thyroid cancer proliferation, migration and invasion. “We continue to be encouraged by data resulting from studies conducted at multiple research institutions…

TuesdayJan 28, 2020 1:19 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, possesses a unique advantage over its competition in the form of samples and access to historical data on clinical outcomes. This data could enable POAI to produce value to pharmaceutical companies significantly faster than its competitors. An article discussing the company reads, “Specifically, POAI can leverage two unique proprietary assets, from its acquisition of Helomics, which virtually eliminate development risk, a factor that considerably weighs on competitors’ efforts in the precision medicine space. First, Predictive Oncology possesses a clinically validated, tumor-profiling platform built from data derived from actual…

TuesdayJan 28, 2020 9:18 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced the closing of its common stock offering priced at-the-market under Nasdaq rules. Genprex sold a total of 7,620,000 shares of its common stock at a price of $1.05 each, resulting in total gross proceeds of $8 million before deducting commissions and estimated offering expenses. The company plans to use the proceeds toward the advancement of its lead clinical programs in non-small cell lung cancer (“NSCLC”) and…

FridayJan 24, 2020 1:48 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Inks LOI to Acquire Quantitative Medicine

Predictive Oncology (NASDAQ: POAI), a data and artificial-intelligence- (“AI”) driven, discovery-services company, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company. By combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling proficiency and data, company management believes the acquisition will assist in fast-tracking the commercialization of its AI-driven technology and services. Subject to the negotiation of a definitive agreement and other terms and conditions, the transaction is anticipated to be completed within the first two quarters of 2020. “Our goal is to provide researchers in…

ThursdayJan 23, 2020 11:49 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market

Genprex (NASDAQ: GNPX), a clinical stage gene therapy company developing a new and potentially life-saving approach to treating some of the world’s most deadly cancers based upon a novel proprietary technology platform, today announced its entry into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock. According to the update, the offering is priced at-the-market under Nasdaq rules with par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering. Gross proceeds will be approximately $8,000,000 before deducting fees and other estimated offering expenses,…

TuesdayJan 21, 2020 10:28 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company utilizing a unique, nonviral proprietary platform designed to deliver tumor suppressor genes to cancer cells, today announced that the U.S Food and Drug Administration (FDA) has granted Fast Track Designation for Genprex’s Oncoprex(TM) immunogene therapy in combination with EGFR inhibitor osimertinib (AstraZeneca’s Tagrisso(R)). Tagrisso(R), with worldwide sales of $1.86 billion in 2018 and $2.31 billion in the first 9 months of 2019, is currently AstraZeneca’s highest grossing product for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone. Genprex has treated more…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Meets Nasdaq Minimum Bid Price Requirement, Regains Compliance

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Focus Clinical Efforts on Oncoprex(TM) in Combination with Osimertinib for Treatment of Non-Small Cell Lung Cancer

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Launches Innovative Culture Media for Growing Ovarian Tumor Cells in the Lab

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at NobleCon16 Investor Conference

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Independent Research Findings on TUSC2 as a Potential Target and Biomarker for Thyroid Carcinoma

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Unique Competitive Advantage

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Closes $8M At-The-Market Offering

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Inks LOI to Acquire Quantitative Medicine

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Prices $8M Common Stock Offering At-The-Market

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Receipt of U.S. FDA Fast Track Designation for Immunogene Therapy that Targets Lung Cancer

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search